Previous 10 | Next 10 |
2023-03-24 07:29:58 ET GSK ( NYSE: GSK ) said it disagrees with a California state court ruling in respect to the Goetz case related to the company's heartburn drug Zantac (ranitidine). The British pharma giant said that after 13 epidemiological studies conducted lookin...
COYA 302 is an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig (Abatacept). COYA 302 has a dual mechanism of action intended to suppress the chronic and sustained inflammation underlying certain neurodegenerative diseases. COYA 301 ...
Summary Aikya Investment Management is an independent, employee-owned, investment management company that specialises in managing Emerging Markets equity portfolios. We believe that by investing with good stewards of capital, we can navigate the volatility of Emerging Markets whil...
Indian pharma company Dr. Reddy's Laboratories ( NYSE: RDY ) announced an agreement to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group ( OTCPK:MAYNF ) ( OTCPK:MYPHY ) on Monday. Per the terms, Dr. Reddy's ( RDY ) will pay ~$90M...
Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agree...
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...
Summary Growth in key emerging markets, including India and Russian footprint. Positive Q3 FY23 results with top–bottom line growth. Solid FCF conversion and returns on capital. Reinvesting into growth at high rates of return, sporting respectable valuations. Buy thesis suppo...
Summary Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even t...
Featured for the 6 th year in a row as the only Indian pharma company in the Bloomberg Gender-Equality Index (GEI) Included in S&P Global’s Sustainability Yearbook for a 3 rd successive year based on its 2022 Corporate Sustainability Assessment (CSA) The company...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...